期刊
JOURNAL OF BONE AND MINERAL METABOLISM
卷 30, 期 1, 页码 119-123出版社
SPRINGER TOKYO
DOI: 10.1007/s00774-011-0323-3
关键词
Chronic myeloid leukemia; Imatinib; Mesenchymal stem cell; Osteoblast differentiation; PDGFR
资金
- Norwegian Cancer Society
- Norwegian Research Council
- Swedish Research Council [529-2004-6512, 521-2006-5103]
- Swedish federal government under LUA/ALF
- Sahlgrenska University Hospital Foundation
- Novartis
- Bristol-Myers Squibb
Altered bone metabolism has been reported in patients with chronic myeloid leukemia treated with the tyrosine kinase inhibitor imatinib. Several studies have shown that imatinib inhibits the differentiation and activity of osteoclasts in vitro, whereas the effects of imatinib on osteoblast differentiation are less clear. In this study osteoblast differentiation was induced in human mesenchymal stem cells (hMSCs) by treatment with bone morphogenetic protein 2 in vitro. Imatinib inhibited proliferation of hMSCs in a dose-dependent manner. Even though imatinib promoted early osteoblast differentiation assessed by alkaline phosphate activity, mineralization measured by Alizarin Red staining (ARS) was reduced by imatinib. Moreover, the inhibitory effect of imatinib on mineralization was most prominent at low concentrations of imatinib. When we measured the relative mRNA expression levels of Runx2, we found that Runx2 expression was higher in imatinib-treated (5 mu M) cultures at early time points during differentiation. On the other hand, the expression of Osterix late during differentiation was lower in imatinib-treated (5 mu M) cultures, corresponding to the ARS results. Thus, the effect of imatinib on osteoblast differentiation is not only dependent on the drug concentration, but indeed also on the maturation stage of the cells. This finding might partly explain why previous studies on the effects of imatinib osteoblast differentiation have shown different results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据